1
|
Scienti OLPP, Darambara DG. To Reconstruct or Discard: A Comparison of Additive and Subtractive Charge Sharing Correction Algorithms at High and Low X-ray Fluxes. SENSORS (BASEL, SWITZERLAND) 2024; 24:4946. [PMID: 39123992 PMCID: PMC11314781 DOI: 10.3390/s24154946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2024] [Revised: 07/26/2024] [Accepted: 07/27/2024] [Indexed: 08/12/2024]
Abstract
Effective X-ray photon-counting spectral imaging (x-CSI) detector design involves the optimisation of a wide range of parameters both regarding the sensor (e.g., material, thickness and pixel pitch) and electronics (e.g., signal-processing chain and count-triggering scheme). Our previous publications have looked at the role of pixel pitch, sensor thickness and a range of additive charge sharing correction algorithms (CSCAs), and in this work, we compare additive and subtractive CSCAs to identify the advantages and disadvantages. These CSCAs differ in their approach to dealing with charge sharing: additive approaches attempt to reconstruct the original event, whilst subtractive approaches discard the shared events. Each approach was simulated on data from a wide range of x-CSI detector designs (pixel pitches 100-600 µm, sensor thickness 1.5 mm) and X-ray fluxes (106-109 photons mm-2 s-1), and their performance was characterised in terms of absolute detection efficiency (ADE), absolute photopeak efficiency (APE), relative coincidence counts (RCC) and binned spectral efficiency (BSE). Differences between the two approaches were explained mechanistically in terms of the CSCA's effect on both charge sharing and pule pileup. At low X-ray fluxes, the two approaches perform similarly, but at higher fluxes, they differ in complex ways. Generally, additive CSCAs perform better on absolute metrics (ADE and APE), and subtractive CSCAs perform better on relative metrics (RCC and BSE). Which approach to use will, thus, depend on the expected operating flux and whether dose efficiency or spectral efficiency is more important for the application in mind.
Collapse
Affiliation(s)
- Oliver L. P. Pickford Scienti
- Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London SM2 5NG, UK;
| | | |
Collapse
|
2
|
Meloni A, Maffei E, Clemente A, De Gori C, Occhipinti M, Positano V, Berti S, La Grutta L, Saba L, Cau R, Bossone E, Mantini C, Cavaliere C, Punzo B, Celi S, Cademartiri F. Spectral Photon-Counting Computed Tomography: Technical Principles and Applications in the Assessment of Cardiovascular Diseases. J Clin Med 2024; 13:2359. [PMID: 38673632 PMCID: PMC11051476 DOI: 10.3390/jcm13082359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2024] [Revised: 04/15/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Spectral Photon-Counting Computed Tomography (SPCCT) represents a groundbreaking advancement in X-ray imaging technology. The core innovation of SPCCT lies in its photon-counting detectors, which can count the exact number of incoming x-ray photons and individually measure their energy. The first part of this review summarizes the key elements of SPCCT technology, such as energy binning, energy weighting, and material decomposition. Its energy-discriminating ability represents the key to the increase in the contrast between different tissues, the elimination of the electronic noise, and the correction of beam-hardening artifacts. Material decomposition provides valuable insights into specific elements' composition, concentration, and distribution. The capability of SPCCT to operate in three or more energy regimes allows for the differentiation of several contrast agents, facilitating quantitative assessments of elements with specific energy thresholds within the diagnostic energy range. The second part of this review provides a brief overview of the applications of SPCCT in the assessment of various cardiovascular disease processes. SPCCT can support the study of myocardial blood perfusion and enable enhanced tissue characterization and the identification of contrast agents, in a manner that was previously unattainable.
Collapse
Affiliation(s)
- Antonella Meloni
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.M.); (V.P.)
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| | - Erica Maffei
- Department of Radiology, Istituto di Ricovero e Cura a Carattere Scientifico SYNLAB SDN, 80131 Naples, Italy; (E.M.); (C.C.); (B.P.)
| | - Alberto Clemente
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| | - Carmelo De Gori
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| | - Mariaelena Occhipinti
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| | - Vicenzo Positano
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.M.); (V.P.)
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| | - Sergio Berti
- Diagnostic and Interventional Cardiology Department, Fondazione G. Monasterio CNR-Regione Toscana, 54100 Massa, Italy;
| | - Ludovico La Grutta
- Department of Radiology, University Hospital “P. Giaccone”, 90127 Palermo, Italy;
| | - Luca Saba
- Department of Radiology, University Hospital of Cagliari, 09042 Monserrato (CA), Italy; (L.S.); (R.C.)
| | - Riccardo Cau
- Department of Radiology, University Hospital of Cagliari, 09042 Monserrato (CA), Italy; (L.S.); (R.C.)
| | - Eduardo Bossone
- Department of Cardiology, Ospedale Cardarelli, 80131 Naples, Italy;
| | - Cesare Mantini
- Department of Radiology, “G. D’Annunzio” University, 66100 Chieti, Italy;
| | - Carlo Cavaliere
- Department of Radiology, Istituto di Ricovero e Cura a Carattere Scientifico SYNLAB SDN, 80131 Naples, Italy; (E.M.); (C.C.); (B.P.)
| | - Bruna Punzo
- Department of Radiology, Istituto di Ricovero e Cura a Carattere Scientifico SYNLAB SDN, 80131 Naples, Italy; (E.M.); (C.C.); (B.P.)
| | - Simona Celi
- BioCardioLab, Fondazione G. Monasterio CNR-Regione Toscana, 54100 Massa, Italy;
| | - Filippo Cademartiri
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.C.); (C.D.G.); (M.O.)
| |
Collapse
|
3
|
Douek PC, Boccalini S, Oei EHG, Cormode DP, Pourmorteza A, Boussel L, Si-Mohamed SA, Budde RPJ. Clinical Applications of Photon-counting CT: A Review of Pioneer Studies and a Glimpse into the Future. Radiology 2023; 309:e222432. [PMID: 37787672 PMCID: PMC10623209 DOI: 10.1148/radiol.222432] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Revised: 03/24/2023] [Accepted: 04/11/2023] [Indexed: 10/04/2023]
Abstract
CT systems equipped with photon-counting detectors (PCDs), referred to as photon-counting CT (PCCT), are beginning to change imaging in several subspecialties, such as cardiac, vascular, thoracic, and musculoskeletal radiology. Evidence has been building in the literature underpinning the many advantages of PCCT for different clinical applications. These benefits derive from the distinct features of PCDs, which are made of semiconductor materials capable of converting photons directly into electric signal. PCCT advancements include, among the most important, improved spatial resolution, noise reduction, and spectral properties. PCCT spatial resolution on the order of 0.25 mm allows for the improved visualization of small structures (eg, small vessels, arterial walls, distal bronchi, and bone trabeculations) and their pathologies, as well as the identification of previously undetectable anomalies. In addition, blooming artifacts from calcifications, stents, and other dense structures are reduced. The benefits of the spectral capabilities of PCCT are broad and include reducing radiation and contrast material dose for patients. In addition, multiple types of information can be extracted from a single data set (ie, multiparametric imaging), including quantitative data often regarded as surrogates of functional information (eg, lung perfusion). PCCT also allows for a novel type of CT imaging, K-edge imaging. This technique, combined with new contrast materials specifically designed for this modality, opens the door to new applications for imaging in the future.
Collapse
Affiliation(s)
| | | | - Edwin H. G. Oei
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - David P. Cormode
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Amir Pourmorteza
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Loic Boussel
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Salim A. Si-Mohamed
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Ricardo P. J. Budde
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| |
Collapse
|
4
|
Cademartiri F, Meloni A, Pistoia L, Degiorgi G, Clemente A, Gori CD, Positano V, Celi S, Berti S, Emdin M, Panetta D, Menichetti L, Punzo B, Cavaliere C, Bossone E, Saba L, Cau R, Grutta LL, Maffei E. Dual-Source Photon-Counting Computed Tomography-Part I: Clinical Overview of Cardiac CT and Coronary CT Angiography Applications. J Clin Med 2023; 12:jcm12113627. [PMID: 37297822 DOI: 10.3390/jcm12113627] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 05/15/2023] [Accepted: 05/17/2023] [Indexed: 06/12/2023] Open
Abstract
The photon-counting detector (PCD) is a new computed tomography detector technology (photon-counting computed tomography, PCCT) that provides substantial benefits for cardiac and coronary artery imaging. Compared with conventional CT, PCCT has multi-energy capability, increased spatial resolution and soft tissue contrast with near-null electronic noise, reduced radiation exposure, and optimization of the use of contrast agents. This new technology promises to overcome several limitations of traditional cardiac and coronary CT angiography (CCT/CCTA) including reduction in blooming artifacts in heavy calcified coronary plaques or beam-hardening artifacts in patients with coronary stents, and a more precise assessment of the degree of stenosis and plaque characteristic thanks to its better spatial resolution. Another potential application of PCCT is the use of a double-contrast agent to characterize myocardial tissue. In this current overview of the existing PCCT literature, we describe the strengths, limitations, recent applications, and promising developments of employing PCCT technology in CCT.
Collapse
Affiliation(s)
| | - Antonella Meloni
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Laura Pistoia
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Giulia Degiorgi
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Alberto Clemente
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Carmelo De Gori
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Vincenzo Positano
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Simona Celi
- BioCardioLab, Department of Bioengineering, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Sergio Berti
- Cardiology Unit, Ospedale del Cuore, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Michele Emdin
- Department of Cardiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Daniele Panetta
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Luca Menichetti
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Bruna Punzo
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Carlo Cavaliere
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Eduardo Bossone
- Department of Cardiology, Ospedale Cardarelli, 80131 Naples, Italy
| | - Luca Saba
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Riccardo Cau
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Ludovico La Grutta
- Department of Radiology, University Hospital "P. Giaccone", 90127 Palermo, Italy
| | - Erica Maffei
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| |
Collapse
|
5
|
Cademartiri F, Meloni A, Pistoia L, Degiorgi G, Clemente A, De Gori C, Positano V, Celi S, Berti S, Emdin M, Panetta D, Menichetti L, Punzo B, Cavaliere C, Bossone E, Saba L, Cau R, Grutta LL, Maffei E. Dual Source Photon-Counting Computed Tomography-Part II: Clinical Overview of Neurovascular Applications. J Clin Med 2023; 12:jcm12113626. [PMID: 37297821 DOI: 10.3390/jcm12113626] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 05/15/2023] [Accepted: 05/18/2023] [Indexed: 06/12/2023] Open
Abstract
Photon-counting detector (PCD) is a novel computed tomography detector technology (photon-counting computed tomography-PCCT) that presents many advantages in the neurovascular field, such as increased spatial resolution, reduced radiation exposure, and optimization of the use of contrast agents and material decomposition. In this overview of the existing literature on PCCT, we describe the physical principles, the advantages and the disadvantages of conventional energy integrating detectors and PCDs, and finally, we discuss the applications of the PCD, focusing specifically on its implementation in the neurovascular field.
Collapse
Affiliation(s)
| | - Antonella Meloni
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Laura Pistoia
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Giulia Degiorgi
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Alberto Clemente
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Carmelo De Gori
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Vincenzo Positano
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Simona Celi
- BioCardioLab, Department of Bioengineering, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Sergio Berti
- Cardiology Unit, Ospedale del Cuore, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Michele Emdin
- Department of Cardiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Daniele Panetta
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Luca Menichetti
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Bruna Punzo
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Carlo Cavaliere
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Eduardo Bossone
- Department of Cardiology, Ospedale Cardarelli, 80131 Naples, Italy
| | - Luca Saba
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Riccardo Cau
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Ludovico La Grutta
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties-ProMISE, Department of Radiology, University Hospital "P. Giaccone", 90127 Palermo, Italy
| | - Erica Maffei
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| |
Collapse
|
6
|
Kumar D, Moghiseh M, Chitcholtan K, Mutreja I, Lowe C, Kaushik A, Butler A, Sykes P, Anderson N, Raja A. LHRH conjugated gold nanoparticles assisted efficient ovarian cancer targeting evaluated via spectral photon-counting CT imaging: a proof-of-concept research. J Mater Chem B 2023; 11:1916-1928. [PMID: 36744575 DOI: 10.1039/d2tb02416k] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Emerging multifunctional nanoparticulate formulations take advantage of nano-meter scale size and surface chemistry to work as a therapeutic delivery agent and a diagnostic tool for non-invasive real-time monitoring using imaging technologies. Here, we evaluate the selective uptake of 18 nm and 80 nm sized gold nanoparticles (AuNPs) by SKOV3 (4 times higher) ovarian cancer (OC) cells (compared to OVCAR5) in vitro, quantified by inductively coupled plasma (ICP) and MARS spectral photon-counting CT imaging (MARS SPCCT). Based on in vitro analysis, pristine AuNPs (18 nm) and surface modified AuNPs (18 nm) were chosen as a contrast agent for MARS SPCCT. The chemical analysis by FTIR spectroscopy confirmed the luteinizing hormone-releasing hormone (LHRH) conjugation to the AuNPs surface. For the first time, LHRH conjugated AuNPs were used for in vitro and selective in vivo OC targeting. The ICP-MS analysis confirmed preferential uptake of LHRH modified AuNPs by organs residing in the abdominal cavity with OC nodules (pancreas: 0.46 ng mg-1, mesentery: 0.89 ng mg-1, ovary: 1.43 ng mg-1, and abdominal wall: 2.12 ng mg-1) whereas the MARS SPCCT analysis suggested scattered accumulation of metal around the abdominal cavity. Therefore, the study showed the exciting potential of LHRH conjugated AuNPs to target ovarian cancer and also as a potential contrast agent for novel SPCCT imaging technology.
Collapse
Affiliation(s)
- Dhiraj Kumar
- Division of Pediatrics Dentistry, School of Dentistry, University of Minnesota, 515 Delaware St SE, Minneapolis, Minnesota, 55455, USA. .,Department of Obstetrics and Gynaecology, Christchurch Women Hospital, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand
| | - Mahdieh Moghiseh
- Department of Radiology, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand.,MARS Bioimaging Limited, Christchurch, New Zealand
| | - Kenny Chitcholtan
- Department of Obstetrics and Gynaecology, Christchurch Women Hospital, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand
| | - Isha Mutreja
- Minnesota Dental Research Center for Biomaterials and Biomechanics (MDRCBB), School of Dentistry, University of Minnesota, 515 Delaware St SE, Minneapolis, Minnesota, 55455, USA
| | - Chiara Lowe
- Department of Radiology, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand.,MARS Bioimaging Limited, Christchurch, New Zealand
| | - Ajeet Kaushik
- NanoBiotech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, FL, 33805, USA
| | - Anthony Butler
- Department of Radiology, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand.,MARS Bioimaging Limited, Christchurch, New Zealand
| | - Peter Sykes
- Department of Obstetrics and Gynaecology, Christchurch Women Hospital, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand
| | - Nigel Anderson
- Department of Radiology, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand
| | - Aamir Raja
- Department of Radiology, University of Otago Christchurch, 2 Riccarton Ave, School of Medicine, Christchurch, New Zealand.,Department of Physics, Khalifa University, Abu Dhabi, United Arab Emirates
| |
Collapse
|
7
|
Moghiseh M, Searle E, Dixit D, Kim J, Dong YC, Cormode DP, Butler A, Gieseg SP. Spectral Photon-Counting CT Imaging of Gold Nanoparticle Labelled Monocytes for Detection of Atherosclerosis: A Preclinical Study. Diagnostics (Basel) 2023; 13:diagnostics13030499. [PMID: 36766602 PMCID: PMC9914700 DOI: 10.3390/diagnostics13030499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/20/2023] [Accepted: 01/24/2023] [Indexed: 01/31/2023] Open
Abstract
A key process in the development of atherosclerotic plaques is the recruitment of monocytes into the artery wall. Using spectral photon-counting computed tomography we examine whether monocyte deposition within the artery wall of ApoE-/- mouse can be detected. Primary mouse monocytes were labelled by incubating them with 15 nm gold nanoparticles coated with 11-mercaptoundecanoic acid The monocyte uptake of the particle was confirmed by electron microscopy of the cells before injection into 6-week-old apolipoprotein E deficient (ApoE-/-) mouse that had been fed with the Western diet for 10 weeks. Four days following injection, the mouse was sacrificed and imaged using a MARS spectral photon counting computed tomography scanner with a spectral range of 7 to 120 KeV with five energy bins. Imaging analysis showed the presence of X-ray dense material within the mouse aortic arch which was consistent with the spectral characteristic of gold rather than calcium. The imaging is interpreted as showing the deposition of gold nanoparticles containing monocytes within the mouse aorta. The results of our study determined that spectral photon-counting computed tomography could provide quantitative information about gold nanoparticles labelled monocytes in voxels of 90 × 90 × 90 µm3. The imaging was consistent with previous micro-CT and electron microscopy of mice using the same nanoparticles. This study demonstrates that spectral photon-counting computed tomography, using a MARS small bore scanner, can detect a fundamental atherogenic process within mouse models of atherogenesis. The present study demonstrates the feasibility of spectral photon-counting computed tomography as an emerging molecular imaging modality to detect atherosclerotic disease.
Collapse
Affiliation(s)
- Mahdieh Moghiseh
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Correspondence: (M.M.); (S.P.G.)
| | - Emily Searle
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
- Department of Physics and Astronomy, University of Canterbury, Christchurch 8041, New Zealand
| | - Devyani Dixit
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
| | - Johoon Kim
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yuxi C. Dong
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - David P. Cormode
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Anthony Butler
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Department of Physics and Astronomy, University of Canterbury, Christchurch 8041, New Zealand
- European Organization for Nuclear Research (CERN), 1211 Meyrin, Switzerland
| | - Steven P. Gieseg
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
- European Organization for Nuclear Research (CERN), 1211 Meyrin, Switzerland
- Correspondence: (M.M.); (S.P.G.)
| | | |
Collapse
|
8
|
Li Y, Younis MH, Wang H, Zhang J, Cai W, Ni D. Spectral computed tomography with inorganic nanomaterials: State-of-the-art. Adv Drug Deliv Rev 2022; 189:114524. [PMID: 36058350 PMCID: PMC9664656 DOI: 10.1016/j.addr.2022.114524] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 08/09/2022] [Accepted: 08/27/2022] [Indexed: 01/24/2023]
Abstract
Recently, spectral computed tomography (CT) technology has received great interest in the field of radiology. Spectral CT imaging utilizes the distinct, energy-dependent X-ray absorption properties of substances in order to provide additional imaging information. Dual-energy CT and multi-energy CT (Spectral CT) are capable of constructing monochromatic energy images, material separation images, energy spectrum curves, constructing effective atomic number maps, and more. However, poor contrast, due to neighboring X-ray attenuation of organs and tissues, is still a challenge to spectral CT. Hence, contrast agents (CAs) are applied for better differentiation of a given region of interest (ROI). Currently, many different kinds of inorganic nanoparticulate CAs for spectral CT have been developed due to the limitations of clinical iodine (I)-based contrast media, leading to the conclusion that inorganic nanomedicine applied to spectral CT will be a powerful collaboration both in basic research and in clinics. In this review, the underlying principles and types of spectral CT techniques are discussed, and some evolving clinical diagnosis applications of spectral CT techniques are introduced. In particular, recent developments in inorganic CAs used for spectral CT are summarized. Finally, the challenges and future developments of inorganic nanomedicine in spectral CT are briefly discussed.
Collapse
Affiliation(s)
- Yuhan Li
- School of Medicine, Shanghai University, No. 99 Shangda Rd, Shanghai 200444, PR China
| | - Muhsin H Younis
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, WI 53705, United States
| | - Han Wang
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin 2nd Rd, Shanghai 200025, PR China
| | - Jian Zhang
- School of Medicine, Shanghai University, No. 99 Shangda Rd, Shanghai 200444, PR China; Shanghai Universal Medical Imaging Diagnostic Center, Bldg 8, No. 406 Guilin Rd, Shanghai 200233, PR China.
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, WI 53705, United States.
| | - Dalong Ni
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin 2nd Rd, Shanghai 200025, PR China.
| |
Collapse
|
9
|
Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies. Cancers (Basel) 2022; 14:cancers14133047. [PMID: 35804818 PMCID: PMC9264814 DOI: 10.3390/cancers14133047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 06/03/2022] [Accepted: 06/17/2022] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Hematological malignancies (HMs) cover 50% of all malignancies, and people of all ages can be affected by these deadly diseases. In many cases, conventional diagnostic tools fail to diagnose HMs at an early stage, due to heterogeneity and the long-term indolent phase of HMs. Therefore, many patients start their treatment at the late stage of HMs and have poor survival. Gold nanomaterials (GNMs) have shown promise as a cancer theranostic agent. GNMs are 1 nm to 100 nm materials having magnetic resonance and surface-plasmon-resonance properties. GNMs conjugated with antibodies, nucleic acids, peptides, photosensitizers, chemotherapeutic drugs, synthetic-drug candidates, bioactive compounds, and other theranostic biomolecules may enhance the efficacy and efficiency of both traditional and advanced theranostic approaches to combat HMs. Abstract Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.
Collapse
|
10
|
Pickford Scienti OLP, Darambara DG. An Overview of X-ray Photon Counting Spectral Imaging (x-CSI) with a Focus on Gold Nanoparticle Quantification in Oncology. J Imaging 2021; 8:4. [PMID: 35049845 PMCID: PMC8778032 DOI: 10.3390/jimaging8010004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/24/2021] [Accepted: 12/27/2021] [Indexed: 02/07/2023] Open
Abstract
This review article offers an overview of the differences between traditional energy integrating (EI) X-ray imaging and the new technique of X-ray photon counting spectral imaging (x-CSI). The review is motivated by the need to image gold nanoparticles (AuNP) in vivo if they are to be used clinically to deliver a radiotherapy dose-enhancing effect (RDEE). The aim of this work is to familiarise the reader with x-CSI as a technique and to draw attention to how this technique will need to develop to be of clinical use for the described oncological applications. This article covers the conceptual differences between x-CSI and EI approaches, the advantages of x-CSI, constraints on x-CSI system design, and the achievements of x-CSI in AuNP quantification. The results of the review show there are still approximately two orders of magnitude between the AuNP concentrations used in RDEE applications and the demonstrated detection limits of x-CSI. Two approaches to overcome this were suggested: changing AuNP design or changing x-CSI system design. Optimal system parameters for AuNP detection and general spectral performance as determined by simulation studies were different to those used in the current x-CSI systems, indicating potential gains that may be made with this approach.
Collapse
Affiliation(s)
- Oliver L. P. Pickford Scienti
- Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London SM2 5NG, UK;
| | | |
Collapse
|
11
|
Sawall S, Amato C, Klein L, Wehrse E, Maier J, Kachelrieß M. Toward molecular imaging using spectral photon-counting computed tomography? Curr Opin Chem Biol 2021; 63:163-170. [PMID: 34051510 DOI: 10.1016/j.cbpa.2021.04.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 04/07/2021] [Indexed: 12/22/2022]
Abstract
Molecular imaging is a valuable tool in drug discovery and development, early screening and diagnosis of diseases, and therapy assessment among others. Although many different imaging modalities are in use today, molecular imaging with computed tomography (CT) is still challenging owing to its low sensitivity and soft tissue contrast compared with other modalities. Recent technical advances, particularly the introduction of spectral photon-counting detectors, might allow overcoming these challenges. Herein, the fundamentals and recent advances in CT relevant to molecular imaging are reviewed and potential future preclinical and clinical applications are highlighted. The review concludes with a discussion of potential future advancements of CT for molecular imaging.
Collapse
Affiliation(s)
- Stefan Sawall
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany.
| | - Carlo Amato
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Laura Klein
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Physical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 226, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Eckhard Wehrse
- Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Joscha Maier
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Marc Kachelrieß
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| |
Collapse
|
12
|
Kukkar D, Kukkar P, Kumar V, Hong J, Kim KH, Deep A. Recent advances in nanoscale materials for antibody-based cancer theranostics. Biosens Bioelectron 2020; 173:112787. [PMID: 33190049 DOI: 10.1016/j.bios.2020.112787] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Revised: 10/08/2020] [Accepted: 10/30/2020] [Indexed: 02/07/2023]
Abstract
The quest for advanced management tools or options of various cancers has been on the rise to efficiently reduce their risks of mortality without the demerits of conventional treatments (e.g., undesirable side effects of the medications on non-target tissues, non-targeted distribution, slow clearance of the administered drugs, and the development of drug resistance over the duration of therapy). In this context, nanomaterials-antibody conjugates can offer numerous advantages in the development of cancer theranostics over conventional delivery systems (e.g., highly specific and enhanced biodistribution of the drug in targeted tissues, prolonged systemic circulation, low toxicity, and minimally invasive molecular imaging). This review comprehensively discusses and evaluates recent advances in the application of nanomaterial-antibody bioconjugates for cancer theranostics for the further advancement in the control of diverse cancerous diseases. Further, discussion is expanded to cover the various challenges and limitations associated with the design and development of nanomaterial-antibody conjugates applicable towards better management of cancer.
Collapse
Affiliation(s)
- Deepak Kukkar
- Department of Nanotechnology, Sri Guru Granth Sahib World University, Fatehgarh Sahib, Punjab, 140406, India
| | - Preeti Kukkar
- Department of Chemistry, Mata Gujri College, Fatehgarh Sahib, Punjab, 140406, India
| | - Vanish Kumar
- National Agri-Food Biotechnology Institute (NABI), S.A.S. Nagar, Punjab, 140306, India
| | - Jongki Hong
- College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Seoul, 02447, Republic of Korea
| | - Ki-Hyun Kim
- Department of Civil and Environmental Engineering, Hanyang University, Seoul, 04763 Republic of Korea.
| | - Akash Deep
- Central Scientific Instruments Organization (CSIR-CSIO), Sector 30 C, Chandigarh, 160030, India.
| |
Collapse
|
13
|
Pickford Scienti OLP, Bamber JC, Darambara DG. CdTe Based Energy Resolving, X-ray Photon Counting Detector Performance Assessment: The Effects of Charge Sharing Correction Algorithm Choice. SENSORS (BASEL, SWITZERLAND) 2020; 20:E6093. [PMID: 33120903 PMCID: PMC7663711 DOI: 10.3390/s20216093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 10/23/2020] [Accepted: 10/24/2020] [Indexed: 11/17/2022]
Abstract
Most modern energy resolving, photon counting detectors employ small (sub 1 mm) pixels for high spatial resolution and low per pixel count rate requirements. These small pixels can suffer from a range of charge sharing effects (CSEs) that degrade both spectral analysis and imaging metrics. A range of charge sharing correction algorithms (CSCAs) have been proposed and validated by different groups to reduce CSEs, however their performance is often compared solely to the same system when no such corrections are made. In this paper, a combination of Monte Carlo and finite element methods are used to compare six different CSCAs with the case where no CSCA is employed, with respect to four different metrics: absolute detection efficiency, photopeak detection efficiency, relative coincidence counts, and binned spectral efficiency. The performance of the various CSCAs is explored when running on systems with pixel pitches ranging from 100 µm to 600µm, in 50 µm increments, and fluxes from 106 to 108 photons mm-2 s-1 are considered. Novel mechanistic explanations for the difference in performance of the various CSCAs are proposed and supported. This work represents a subset of a larger project in which pixel pitch, thickness, flux, and CSCA are all varied systematically.
Collapse
Affiliation(s)
- Oliver L. P. Pickford Scienti
- Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London SM2 5NG, UK; (J.C.B.); (D.G.D.)
| | | | | |
Collapse
|
14
|
Jacobsen MC, Thrower SL. Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. Med Phys 2020; 47:3752-3771. [PMID: 32453879 PMCID: PMC8495770 DOI: 10.1002/mp.14241] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 04/20/2020] [Accepted: 05/07/2020] [Indexed: 12/21/2022] Open
Abstract
Computed tomography (CT) technology has rapidly evolved since its introduction in the 1970s. It is a highly important diagnostic tool for clinicians as demonstrated by the significant increase in utilization over several decades. However, much of the effort to develop and advance CT applications has been focused on improving visual sensitivity and reducing radiation dose. In comparison to these areas, improvements in quantitative CT have lagged behind. While this could be a consequence of the technological limitations of conventional CT, advanced dual-energy CT (DECT) and photon-counting detector CT (PCD-CT) offer new opportunities for quantitation. Routine use of DECT is becoming more widely available and PCD-CT is rapidly developing. This review covers efforts to address an unmet need for improved quantitative imaging to better characterize disease, identify biomarkers, and evaluate therapeutic response, with an emphasis on multi-energy CT applications. The review will primarily discuss applications that have utilized quantitative metrics using both conventional and DECT, such as bone mineral density measurement, evaluation of renal lesions, and diagnosis of fatty liver disease. Other topics that will be discussed include efforts to improve quantitative CT volumetry and radiomics. Finally, we will address the use of quantitative CT to enhance image-guided techniques for surgery, radiotherapy and interventions and provide unique opportunities for development of new contrast agents.
Collapse
Affiliation(s)
- Megan C. Jacobsen
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Sara L. Thrower
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| |
Collapse
|
15
|
Dykman LA, Khlebtsov NG. Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited]. BIOMEDICAL OPTICS EXPRESS 2019; 10:3152-3182. [PMID: 31467774 PMCID: PMC6706047 DOI: 10.1364/boe.10.003152] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 05/30/2019] [Accepted: 05/30/2019] [Indexed: 05/19/2023]
Abstract
Functionalized gold nanoparticles (GNPs) with controlled geometrical and optical properties have been the subject of intense research and biomedical applications. This review summarizes recent data and topical problems in nanomedicine that are related to the use of variously sized, shaped, and structured GNPs. We focus on three topical fields in current nanomedicine: (1) use of GNP-based nanoplatforms for the targeted delivery of anticancer and antimicrobial drugs and of genes; (2) GNP-based cancer immunotherapy; and (3) combined chemo-, immuno-, and phototherapy. We present a summary of the available literature data and a short discussion of future work.
Collapse
Affiliation(s)
- L A Dykman
- Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, 13 Prospekt Entuziastov, Saratov 410049, Russia
| | - N G Khlebtsov
- Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, 13 Prospekt Entuziastov, Saratov 410049, Russia
- Saratov National Research State University, 83 Ulitsa Astrakhanskaya, Saratov 410012, Russia
| |
Collapse
|